Search
Now showing items 1-6 of 6
Tailoring cocrystal and salt formation and controlling the crystal habit of diflunisal
(American Chemical Society, 2016-09-26)
Crystal habit modification of the drug diflunisal that normally grows into extremely thin, long needles has been achieved by breaking the stacking effect with the help of coformers. Eight new cocrystals are reported, along ...
The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems
(Elsevier, 2016-03-16)
A comprehensive study on the dissolution properties of three co-amorphous sulfamerazine/excipient systems, namely sulfamerazine/deoxycholic acid, sulfamerazine/citric acid and sulfamerazine/sodium taurocholate (SMZ/DA, ...
Unexpected effects of catalytic amounts of additives on crystallization from the gas phase: Depression of the sublimation temperature and polymorph control
(American Chemical Society, 2016-04-11)
Sublimation of carbamazepine, piracetam, diflunisal, and p-minobenzoic acid is enhanced by the presence of additives. Temperature reductions and polymorph control have been observed. Sublimation of carbamazepine containing ...
Oxidative stress induced by Pt(IV) pro-drugs based on the cisplatin scaffold and indole carboxylic acids in axial position
(Nature Publishing Group, 2016-06-11)
The use of Pt(IV) complexes as pro-drugs that are activated by intracellular reduction is a widely investigated approach to overcome the limitations of Pt(II) anticancer agents. A series of ten mono- and bis-carboxylated ...
DNA binding, cleavage and cytotoxicity of a novel dimetallic Fe(III) triaza-cyclononane complex
(Elsevier, 2016-03-03)
A novel bimetallic Fe(III) complex with the bis(triaza-cyclononane) ligand 2,6-bis(1,4,7-triazacyclonon-1-ylmethyl)-4-methylphenol (bcmp) is reported. [Fe-2(bcmp(-H))(mu-OH)Cl-2]Cl-2 (2) contains two octahedral Fe(III) ...
A Cu(II) complex targeting the translocator protein: in vitro and in vivo antitumor potential and mechanistic insights
(Royal Society of Chemistry, 2016-12-01)
A new Cu-based anticancer metallodrug which targets the translocator protein is reported. [CuBr2(TZ6)] elicits a remarkable in vitro cytotoxicity in sensitive and multidrug resistant cell lines and induces a 98% reduction ...